Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Post by TITOOOon Mar 20, 2017 5:16pm
407 Views
Post# 26004234

Oh my Aurora Sky ...

Oh my Aurora Sky ...Aurora has taken on a great deal of debt to jump start the Aurora sky project. The company, with $10.3 million in debt and only $17.7 million in cash, is treading on thin ice compared to its competitors. If the project goes south, other prominent players like Aphria and Canopy can swoop in with more cash and brand recognition to develop higher production capabilities and leave Aurora in the dust. Canopy and Aphria have $68.7 million and $75.2 million cash on hand respectively. Additionally, both companies carry half our Aurora's current debt. We believe it would be uncanny for these two industry leaders to lay around doing nothing while Aurora is building to maximize revenue opportunities upon legalization.

User image

Aurora investors also face risk in the form of a somewhat questionable management team. This management risk was investigated explicitly and elaborately in an article by SA contributor Grumpey Bear Research. The article detailed that CEO Terry Booth has no experience with the marijuana industry and faced a lawsuit in the past for selling his company after giving overly optimistic projections. The article adds that President Steve Dobler also has no relevant experience in the marijuana business and was noted by Grumpey Bear as a past business partner of Booth. Grumpey Bear remarked that ex-director Marc Levy worked to "aggressively promote Aurora in order to drive the share price higher" before selling his shares and leaving the company in August 2015.

From my following of cannabis tickers for the past year, we've learned that stock prices entirely follow news on legalization and the two highest valued marijuana companies (Canopy and Aphria) are also leaders in sales revenue for the industry.

User image

Since we have no way of forecasting Canadian politics in the short term, we have to look for correlation between sales revenue and stock price. Aurora's first year sales of $3.46 million in 2015 surpassed Aphria's 2015 revenue of $2.72 million by a good margin. If Aurora is able to surpass Apria's current TTM sales revenue in 2017, we believe there is high potential for Aurora to double from its current price in the next 9-12 months. Of course, this capital appreciation would come along more smoothly if upcoming news on legalization are positive. Personally, we do not have the risk tolerance to initiate a position in Aurora. We may buy into Aurora in the future but we'll stick with Canopy and Aphria for now.

Bullboard Posts